On the public citation graph

Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD

https://doi.org/10.1681/asn.2015121377
0 signed · 386 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2014.6634openalex-snapshot
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
inferredcites →https://doi.org/10.1001/jamainternmed.2015.7193openalex-snapshot
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
inferredcites →https://doi.org/10.1001/jamainternmed.2015.7927openalex-snapshot
Adverse Effects Associated With Proton Pump Inhibitors
inferredcites →https://doi.org/10.1002/9781118707999openalex-snapshot
Textbook of Pharmacoepidemiology
inferredcites →https://doi.org/10.1002/pds.2311openalex-snapshot
The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety
inferredcites →https://doi.org/10.1002/pds.3334openalex-snapshot
The incident user design in comparative effectiveness research
inferredcites →https://doi.org/10.1002/sim.2580openalex-snapshot
A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study
inferredcites →https://doi.org/10.1007/s11606-013-2345-0openalex-snapshot
Proton Pump Inhibitor Prescriptions and Subsequent Use in US Veterans Diagnosed with Gastroesophageal Reflux Disease
inferredcites →https://doi.org/10.1016/0895-4356(94)90170-8openalex-snapshot
Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research
inferredcites →https://doi.org/10.1016/j.amjmed.2013.02.036openalex-snapshot
Hypomagnesemia and the Risk of Death and GFR Decline in Chronic Kidney Disease
inferredcites →https://doi.org/10.1016/j.annepidem.2014.01.004openalex-snapshot
Proton-pump inhibitor use and hip fractures in men: a population-based case-control study
inferredcites →https://doi.org/10.1016/j.jclinepi.2005.07.004openalex-snapshot
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods
inferredcites →https://doi.org/10.1016/j.kint.2015.12.034openalex-snapshot
Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression
inferredcites →https://doi.org/10.1016/s0140-6736(06)68041-0openalex-snapshot
Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis
inferredcites →https://doi.org/10.1038/ki.2010.89openalex-snapshot
Acute interstitial nephritis
inferredcites →https://doi.org/10.1038/ki.2011.379openalex-snapshot
Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1038/ki.2012.418openalex-snapshot
Prediction of renal end points in chronic kidney disease
inferredcites →https://doi.org/10.1038/ki.2012.452openalex-snapshot
Proton-pump inhibitor use is associated with low serum magnesium concentrations
inferredcites →https://doi.org/10.1038/ki.2014.331openalex-snapshot
Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease
inferredcites →https://doi.org/10.1038/ki.2014.74openalex-snapshot
A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use
inferredcites →https://doi.org/10.1038/nrneph.2010.71openalex-snapshot
Drug-induced acute interstitial nephritis
inferredcites →https://doi.org/10.1046/j.1523-1755.2001.060002804.xopenalex-snapshot
Drug-induced acute interstitial nephritis
inferredcites →https://doi.org/10.1053/j.ajkd.2015.05.012openalex-snapshot
Proton Pump Inhibitors and Hypomagnesemia in the General Population: A Population-Based Cohort Study
inferredcites →https://doi.org/10.1053/j.ajkd.2016.02.039openalex-snapshot
Estimated GFR Trajectories of People Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality
inferredcites →https://doi.org/10.1056/nejmp1014427openalex-snapshot
Developing the Sentinel System — A National Resource for Evidence Development
inferredcites →https://doi.org/10.1056/nejmp1401664openalex-snapshot
Mini-Sentinel and Regulatory Science — Big Data Rendered Fit and Functional
inferredcites →https://doi.org/10.1080/00273171.2011.568786openalex-snapshot
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
inferredcites →https://doi.org/10.1093/ndt/18.3.570openalex-snapshot
Overuse of acid suppressant drugs in patients with chronic renal failure
inferredcites →https://doi.org/10.1093/ndt/gfh104openalex-snapshot
Propensity scores: help or hype?
inferredcites →https://doi.org/10.1093/ndt/gfh831openalex-snapshot
Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity
inferredcites →https://doi.org/10.1093/qjmed/hcn035openalex-snapshot
Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease
inferredcites →https://doi.org/10.1111/j.1365-2036.2005.02454.xopenalex-snapshot
Long‐term use of acid suppression started inappropriately during hospitalization
inferredcites →https://doi.org/10.1111/j.1365-2125.2007.02927.xopenalex-snapshot
Proton pump inhibitor‐induced acute interstitial nephritis
inferredcites →https://doi.org/10.1136/bmj.39406.449456.beopenalex-snapshot
Overprescribing proton pump inhibitors
inferredcites →https://doi.org/10.1159/000354390openalex-snapshot
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
inferredcites →https://doi.org/10.1159/000468530openalex-snapshot
Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
inferredcites →https://doi.org/10.1161/circoutcomes.113.000359openalex-snapshot
Propensity Score Methods for Confounding Control in Nonexperimental Research
inferredcites →https://doi.org/10.1186/1471-2369-14-150openalex-snapshot
Proton pump inhibitors and acute kidney injury: a nested case–control study
inferredcites →https://doi.org/10.1186/1479-5876-5-21openalex-snapshot
In support of descriptive studies; relevance to translational research
inferredcites →https://doi.org/10.1371/journal.pone.0149283openalex-snapshot
Renal Function Trajectories in Patients with Prior Improved eGFR Slopes and Risk of Death
inferredcites →https://doi.org/10.1586/17512433.2015.1045489openalex-snapshot
Review of select causes of drug-induced AKI
inferredcites →https://doi.org/10.1681/asn.2007080837openalex-snapshot
Acute Kidney Injury Increases Risk of ESRD among Elderly
inferredcites →https://doi.org/10.1681/asn.2014121218openalex-snapshot
Predictors of Recurrent AKI
inferredcites →https://doi.org/10.18043/ncm.69.1.35openalex-snapshot
Veterans Affairs Research and Development: Using Science to Improve Health Care for Veterans
inferredcites →https://doi.org/10.2215/cjn.04480415openalex-snapshot
Rate of Kidney Function Decline and Risk of Hospitalizations in Stage 3A CKD
inferredcites →https://doi.org/10.2215/cjn.06711208openalex-snapshot
The Nexus of Acute Kidney Injury, Chronic Kidney Disease, and World Kidney Day 2009
inferredcites →https://doi.org/10.2215/cjn.09320913openalex-snapshot
Relation of Serum Lipids and Lipoproteins with Progression of CKD
inferredcites →https://doi.org/10.2337/dc12-0226openalex-snapshot
Hypomagnesemia in Type 2 Diabetic Nephropathy
inferredcites →https://doi.org/10.5414/cnp63429openalex-snapshot
Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2
inferredcites →https://doi.org/10.5414/cnp68065openalex-snapshot
Proton pump inhibitors and the kidney: critical review
inferredcites →https://doi.org/10.5414/cnp71375openalex-snapshot
The link between lower serum magnesium and kidney function in patients with diabetes mellitus Type 2 deserves a closer look
inferredcites →https://doi.org/10.7326/0003-4819-150-9-200905050-00006openalex-snapshot
A New Equation to Estimate Glomerular Filtration Rate
inferredcites →https://doi.org/10.9778/cmajo.20140074openalex-snapshot
Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4015292openalex-extracted
Zn(II) Complexes Bearing Thiophenyl and Furyl Derived C 2-Symmetric Ligands: Synthesis, Characterization, Urease Inhibitory Activities and Molecular Docking
inferred← citeshttps://doi.org/10.1001/jamainternmed.2021.2488openalex-snapshot
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.33953openalex-snapshot
Temporal Trends in Incidence Rates of Lower Extremity Amputation and Associated Risk Factors Among Patients Using Veterans Health Administration Services From 2008 to 2018
inferred← citeshttps://doi.org/10.1002/ccr3.5432openalex-snapshot
Acute interstitial nephritis observed with three different triggering agents
inferred← citeshttps://doi.org/10.1002/cpt.1762openalex-snapshot
Proton Pump Inhibitors Augment the Risk of Major Adverse Cardiovascular Events and End‐Stage Renal Disease in Patients With Acute Kidney Injury After Temporary Dialysis
inferred← citeshttps://doi.org/10.1002/cpt.758openalex-snapshot
Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease
inferred← citeshttps://doi.org/10.1002/hsr2.73217openalex-snapshot
PPI Misuse in Bangladesh: Confronting a Silent Epidemic Through Deprescribing and Regulatory Reform—A Policy Perspective
inferred← citeshttps://doi.org/10.1002/jcph.1585openalex-snapshot
Proton Pump Inhibitor Use Before ICU Admission Is Not Associated With Mortality of Critically Ill Patients
inferred← citeshttps://doi.org/10.1002/lary.27916openalex-snapshot
Practice patterns of reflux medication prescriptions in otolaryngology compared to other specialties
inferred← citeshttps://doi.org/10.1002/lary.28506openalex-snapshot
The Reflux Symptom Index and Symptom Overlap in Dysphonic Patients
inferred← citeshttps://doi.org/10.1002/lio2.187openalex-snapshot
Proton pump inhibitors: Review of reported risks and controversies
inferred← citeshttps://doi.org/10.1002/ncp.10181openalex-snapshot
Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome
inferred← citeshttps://doi.org/10.1002/pds.4684openalex-snapshot
Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints
inferred← citeshttps://doi.org/10.1002/pds.5101openalex-snapshot
Proton pump inhibitors and chronic kidney disease: Reevaluating the evidence from a randomized controlled trial
inferred← citeshttps://doi.org/10.1002/pds.5352openalex-snapshot
Proton pump inhibitors long term use‐trends and patterns over 15 years of a large health maintenance organization
inferred← citeshttps://doi.org/10.1002/phar.2235openalex-snapshot
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study
inferred← citeshttps://doi.org/10.1002/phar.2947openalex-snapshot
Effect of proton pump inhibitors versus histamine‐2 receptor antagonists on acute kidney injury in septic patients at high risk for developing stress ulcers
inferred← citeshttps://doi.org/10.1002/ygh2.394openalex-snapshot
Reporting trends of adverse effects from proton pump inhibitors to the food and drug administration
inferred← citeshttps://doi.org/10.1007/978-3-030-27592-1_14openalex-snapshot
Medical Treatment of GERD
inferred← citeshttps://doi.org/10.1007/978-3-030-43027-6_9openalex-snapshot
What Have You Been Taking? Nephrotoxicity from Medications and Other Chemicals
inferred← citeshttps://doi.org/10.1007/978-3-030-48890-1_31openalex-snapshot
Proton Pump Inhibitor Controversies
inferred← citeshttps://doi.org/10.1007/978-3-030-76419-7_43openalex-snapshot
Gastroenterology and the Kidney
inferred← citeshttps://doi.org/10.1007/978-3-030-93528-3_12openalex-snapshot
Medications to Avoid with Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1007/978-3-031-11665-0_42openalex-snapshot
Tubulointerstitial Nephritis in Children
inferred← citeshttps://doi.org/10.1007/978-3-031-48241-0_8openalex-snapshot
Medical Therapy for Gastroesophageal Reflux Disease
inferred← citeshttps://doi.org/10.1007/978-3-031-66349-9_10openalex-snapshot
What Have You Been Taking? Nephrotoxicity from Drugs and Other Chemicals
inferred← citeshttps://doi.org/10.1007/978-3-032-07868-1_17openalex-snapshot
Use of Proton Pump Inhibitor: Balancing Risks and Benefits
inferred← citeshttps://doi.org/10.1007/978-3-032-08179-7_3openalex-snapshot
Medical Therapy for GERD
inferred← citeshttps://doi.org/10.1007/978-3-319-59352-4_12openalex-snapshot
I Am Tired of Taking Pills for My Reflux, What Else Can I Do? Surgical and Endoscopic Treatment for GERD
inferred← citeshttps://doi.org/10.1007/s00109-024-02429-5openalex-snapshot
Blockade of aryl hydrocarbon receptor restricts omeprazole-induced chronic kidney disease
inferred← citeshttps://doi.org/10.1007/s00210-023-02890-yopenalex-snapshot
Changes in estimated glomerular filtration rate in patients administered proton pump inhibitors: a single-center cohort study
inferred← citeshttps://doi.org/10.1007/s00210-025-04241-5openalex-snapshot
Proton pump inhibitors and risk of hearing loss; a systematic review
inferred← citeshttps://doi.org/10.1007/s00228-023-03534-zopenalex-snapshot
Proton pump inhibitor use: systematic review of global trends and practices
inferred← citeshttps://doi.org/10.1007/s00228-026-04022-wopenalex-snapshot
The association between proton pump inhibitor use and the risk of mortality in patients with kidney disease: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00240-022-01326-1openalex-snapshot
Proton pump inhibitors use and risk of incident nephrolithiasis
inferred← citeshttps://doi.org/10.1007/s00586-026-09767-7openalex-snapshot
Proton pump inhibitor use is associated with increased complications compared to H2-receptor antagonists following multi-level lumbar fusion: a retrospective cohort study
inferred← citeshttps://doi.org/10.1007/s10157-021-02066-zopenalex-snapshot
Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury
inferred← citeshttps://doi.org/10.1007/s10620-017-4633-8openalex-snapshot
From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis
inferred← citeshttps://doi.org/10.1007/s10620-017-4725-5openalex-snapshot
Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis
inferred← citeshttps://doi.org/10.1007/s10620-020-06665-wopenalex-snapshot
Underutilization of Peptic Ulcer Disease Prophylaxis Among Elderly Users of Antiplatelets and Anticoagulants
inferred← citeshttps://doi.org/10.1007/s10620-021-06909-3openalex-snapshot
Inappropriateness of Proton Pump Inhibitors After Hospital Discharge Is Associated with Thirty-Day Hospital Readmission
inferred← citeshttps://doi.org/10.1007/s11096-019-00811-9openalex-snapshot
The use of nephrotoxic drugs in patients with chronic kidney disease
inferred← citeshttps://doi.org/10.1007/s11255-018-1908-8openalex-snapshot
The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis
inferred← citeshttps://doi.org/10.1007/s11606-019-05557-8openalex-snapshot
Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011–2016
inferred← citeshttps://doi.org/10.1007/s11606-024-09213-8openalex-snapshot
Proton Pump Inhibitor Use and Worsening Kidney Function: A Retrospective Cohort Study Including 122,606 Acid-Suppressing Users
inferred← citeshttps://doi.org/10.1007/s11938-017-0115-5openalex-snapshot
Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors
inferred← citeshttps://doi.org/10.1007/s12325-017-0532-9openalex-snapshot
A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
inferred← citeshttps://doi.org/10.1007/s12445-017-0182-9openalex-snapshot
Protonpompremmers slecht voor nieren
inferred← citeshttps://doi.org/10.1007/s12445-017-0210-9openalex-snapshot
PPI’s slecht voor de nieren?
inferred← citeshttps://doi.org/10.1007/s12664-023-01515-9openalex-snapshot
Renal dysfunction in routine proton-pump inhibitor use may be linked to comorbidities: A real-world observational study
inferred← citeshttps://doi.org/10.1007/s40264-017-0579-1openalex-snapshot
A Pharmacoepidemiology Database System for Monitoring Risk Due to the Use of Medicines by New Zealand Primary Care Patients
inferred← citeshttps://doi.org/10.1007/s40264-018-0663-1openalex-snapshot
Use of Proton Pump Inhibitors and the Risk of Acute Kidney Injury Among Patients with Rheumatoid Arthritis: Cohort Study
inferred← citeshttps://doi.org/10.1007/s40264-022-01181-4openalex-snapshot
Incidence, Pathogenesis, and Management of Proton Pump Inhibitor-Induced Nephrotoxicity
inferred← citeshttps://doi.org/10.1007/s40265-019-01110-3openalex-snapshot
The Clinician’s Guide to Proton Pump Inhibitor Related Adverse Events
inferred← citeshttps://doi.org/10.1007/s40266-017-0484-4openalex-snapshot
Drug-Induced Kidney Injury in the Elderly
inferred← citeshttps://doi.org/10.1007/s40267-023-00984-4openalex-snapshot
Prescribe proton pump inhibitors with care and be aware of the signs of nephrotoxicity
inferred← citeshttps://doi.org/10.1007/s40278-016-16874-xopenalex-snapshot
Proton pump inhibitors associated with serious renal outcomes
inferred← citeshttps://doi.org/10.1007/s40620-020-00808-yopenalex-snapshot
Use of proton pump inhibitors in dialysis patients: a double-edged sword?
inferred← citeshttps://doi.org/10.1007/s40620-020-00952-5openalex-snapshot
Analysis of the association between emergency dialysis start in patients with end-stage kidney disease and non-steroidal anti-inflammatory drugs, proton-pump inhibitors, and iodinated contrast agents
inferred← citeshttps://doi.org/10.1007/s40746-023-00290-1openalex-snapshot
Medication-Induced Kidney Injury for the Primary Care Pediatrician
inferred← citeshttps://doi.org/10.1007/s43440-021-00263-xopenalex-snapshot
Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/b978-0-12-809954-4.00038-4openalex-snapshot
The Cell Biology of Gastric Acid Secretion
inferred← citeshttps://doi.org/10.1016/b978-0-12-815389-5.00025-3openalex-snapshot
Mechanisms of drug nephrotoxicity
inferred← citeshttps://doi.org/10.1016/b978-0-323-47871-7.00019-8openalex-snapshot
Medications
inferred← citeshttps://doi.org/10.1016/b978-0-323-49687-2.00036-9openalex-snapshot
Urinary Tract Disorders
inferred← citeshttps://doi.org/10.1016/j.amjms.2021.05.017openalex-snapshot
The Effect of Proton Pump Inhibitor Use on the Course of Kidney Function in Patients with Chronic Kidney Disease Stages G3a to G4
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115149openalex-snapshot
Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients – A review
inferred← citeshttps://doi.org/10.1016/j.cegh.2017.12.008openalex-snapshot
Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies
inferred← citeshttps://doi.org/10.1016/j.cgh.2016.09.013openalex-snapshot
Montelukast Does not Maintain Symptom Remission After Topical Steroid Therapy for Eosinophilic Esophagitis
inferred← citeshttps://doi.org/10.1016/j.cgh.2021.01.014openalex-snapshot
The Mortality Risk of Proton Pump Inhibitors in 1.9 Million US Seniors: An Extended Cox Survival Analysis
inferred← citeshttps://doi.org/10.1016/j.diabres.2018.01.022openalex-snapshot
Association of proton pump inhibitor use with the risk of the development or progression of albuminuria among Japanese patients with diabetes: A prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 16)]
inferred← citeshttps://doi.org/10.1016/j.diabres.2018.11.019openalex-snapshot
Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients
inferred← citeshttps://doi.org/10.1016/j.dld.2020.04.020openalex-snapshot
Latest insights into the hot question of proton pump inhibitor safety – a narrative review
inferred← citeshttps://doi.org/10.1016/j.ejim.2017.03.021openalex-snapshot
Nephrotoxic potential of proton pump inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejim.2019.11.002openalex-snapshot
Use of proton pump inhibitors is associated with an increase in adverse cardiovascular events in patients with hemodialysis: Insight from the kids registry
inferred← citeshttps://doi.org/10.1016/j.ekir.2016.08.016openalex-snapshot
Geographic Variation and US County Characteristics Associated With Rapid Kidney Function Decline
inferred← citeshttps://doi.org/10.1016/j.ekir.2017.01.005openalex-snapshot
Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist?
inferred← citeshttps://doi.org/10.1016/j.ekir.2017.11.001openalex-snapshot
Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients
inferred← citeshttps://doi.org/10.1016/j.ekir.2026.106524openalex-snapshot
Renal Outcomes With Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in CKD
inferred← citeshttps://doi.org/10.1016/j.ekir.2026.106709openalex-snapshot
Causal Effects of Early Discontinuation of Proton Pump Inhibitors on Kidney Failure
inferred← citeshttps://doi.org/10.1016/j.envint.2021.106564openalex-snapshot
Ambient fine particulate matter air pollution and the risk of hospitalization among COVID-19 positive individuals: Cohort study
inferred← citeshttps://doi.org/10.1016/j.giec.2019.12.005openalex-snapshot
Proton Pump Inhibitors
inferred← citeshttps://doi.org/10.1016/j.hpb.2023.02.015openalex-snapshot
Postoperative Proton Pump Inhibitors are associated with a significantly higher rate of delayed gastric emptying after pancreatoduodenectomy
inferred← citeshttps://doi.org/10.1016/j.jointm.2026.06.003openalex-snapshot
Guidelines for the prevention and treatment of stress ulcers in critically ill patients (2026)
inferred← citeshttps://doi.org/10.1016/j.jtumed.2020.03.003openalex-snapshot
The effect of proton pump inhibitors on glycaemic control in diabetic patients
inferred← citeshttps://doi.org/10.1016/j.jvoice.2020.12.001openalex-snapshot
Voice Disorders in Lower Primary School Teachers: An Observational Study
inferred← citeshttps://doi.org/10.1016/j.kint.2016.12.021openalex-snapshot
Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury
inferred← citeshttps://doi.org/10.1016/j.kint.2017.05.010openalex-snapshot
The Authors Reply
inferred← citeshttps://doi.org/10.1016/j.kint.2017.08.033openalex-snapshot
Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus
inferred← citeshttps://doi.org/10.1016/j.kint.2018.04.011openalex-snapshot
Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016
inferred← citeshttps://doi.org/10.1016/j.kint.2021.05.021openalex-snapshot
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
inferred← citeshttps://doi.org/10.1016/j.kint.2022.08.020openalex-snapshot
Particulate matter of air pollution may increase risk of kidney failure in IgA nephropathy
inferred← citeshttps://doi.org/10.1016/j.lpm.2019.02.011openalex-snapshot
Quel est le VRAI risque au long cours des inhibiteurs de la pompe à protons ?
inferred← citeshttps://doi.org/10.1016/j.mad.2020.111392openalex-snapshot
Multimorbidity networks of chronic obstructive pulmonary disease and heart failure in men and women: Evidence from the EpiChron Cohort
inferred← citeshttps://doi.org/10.1016/j.mayocp.2017.10.022openalex-snapshot
Proton Pump Inhibitors: Review of Emerging Concerns
inferred← citeshttps://doi.org/10.1016/j.mayocp.2021.08.017openalex-snapshot
The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy
inferred← citeshttps://doi.org/10.1016/j.nefro.2019.02.003openalex-snapshot
Nuevos retos en las nefritis tubulointersticiales inducidas por fármacos
inferred← citeshttps://doi.org/10.1016/j.nefroe.2019.08.006openalex-snapshot
New challenges in tubulointerstitial nephritis induced by drugs
inferred← citeshttps://doi.org/10.1016/j.nephro.2017.06.005openalex-snapshot
Inhibiteurs de la pompe à protons et rein
inferred← citeshttps://doi.org/10.1016/j.redox.2020.101464openalex-snapshot
Molecular pathways driving omeprazole nephrotoxicity
inferred← citeshttps://doi.org/10.1016/j.sapharm.2019.08.032openalex-snapshot
Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population
inferred← citeshttps://doi.org/10.1016/j.semnephrol.2016.12.009openalex-snapshot
Ensuring Patient Safety During the Transition to ESRD
inferred← citeshttps://doi.org/10.1016/j.tcm.2018.10.008openalex-snapshot
Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe?
inferred← citeshttps://doi.org/10.1016/j.therap.2017.08.003openalex-snapshot
Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis
inferred← citeshttps://doi.org/10.1016/s1155-1968(16)56971-5openalex-snapshot
10.1016/s1155-1968(16)56971-5
inferred← citeshttps://doi.org/10.1016/s1155-1968(21)43979-9openalex-snapshot
10.1016/s1155-1968(21)43979-9
inferred← citeshttps://doi.org/10.1016/s1762-0945(17)68623-6openalex-snapshot
10.1016/s1762-0945(17)68623-6
inferred← citeshttps://doi.org/10.1016/s1877-7856(20)43929-7openalex-snapshot
10.1016/s1877-7856(20)43929-7
inferred← citeshttps://doi.org/10.1016/s2213-8587(23)00171-7openalex-snapshot
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
inferred← citeshttps://doi.org/10.1016/s2542-5196(17)30117-1openalex-snapshot
Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study
inferred← citeshttps://doi.org/10.1016/s2542-5196(18)30140-2openalex-snapshot
The 2016 global and national burden of diabetes mellitus attributable to PM 2·5 air pollution
inferred← citeshttps://doi.org/10.1038/nrgastro.2017.117openalex-snapshot
Proton-pump inhibitors: understanding the complications and risks
inferred← citeshttps://doi.org/10.1038/s41467-021-26513-3openalex-snapshot
Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status
inferred← citeshttps://doi.org/10.1038/s41571-018-0096-xopenalex-snapshot
Chemoprevention of Barrett’s oesophagus: a step closer with PPIs and aspirin
inferred← citeshttps://doi.org/10.1038/s41586-021-03553-9openalex-snapshot
High-dimensional characterization of post-acute sequelae of COVID-19
inferred← citeshttps://doi.org/10.1038/s41591-024-03412-wopenalex-snapshot
Mapping the effectiveness and risks of GLP-1 receptor agonists
inferred← citeshttps://doi.org/10.1038/s41598-017-03069-1openalex-snapshot
Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance
inferred← citeshttps://doi.org/10.1038/s41598-019-39335-7openalex-snapshot
Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis
inferred← citeshttps://doi.org/10.1038/s41598-019-53622-3openalex-snapshot
Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory
inferred← citeshttps://doi.org/10.1038/s41598-020-61115-xopenalex-snapshot
Diabetes Minimally Mediated the Association Between PM2.5 Air Pollution and Kidney Outcomes
inferred← citeshttps://doi.org/10.1038/s41598-021-81388-0openalex-snapshot
Increased colonic K+ excretion through inhibition of the H,K-ATPase type 2 helps reduce plasma K+ level in a murine model of nephronic reduction
inferred← citeshttps://doi.org/10.1038/s41598-023-48430-9openalex-snapshot
Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists
inferred← citeshttps://doi.org/10.1038/s41598-024-69821-6openalex-snapshot
Proton pump inhibitors may increase the risk of cisplatin-induced acute kidney injury in patients with nasopharyngeal carcinoma: a prospective cohort study
inferred← citeshttps://doi.org/10.1038/s41598-024-81208-1openalex-snapshot
Use of consensus clustering to identify distinct subtypes of chronic kidney disease and associated mortality risk
inferred← citeshttps://doi.org/10.1038/s41598-024-83321-7openalex-snapshot
Long-term use of proton pump inhibitors was associated with rapid progression to end stage kidney disease in a Korean nationwide study
inferred← citeshttps://doi.org/10.1038/s41598-025-23527-5openalex-snapshot
Longitudinal trajectories unravel the complex interplay of medication, cardiovascular events, chronic kidney disease, and mortality
inferred← citeshttps://doi.org/10.1053/j.ackd.2016.11.016openalex-snapshot
Medication-Induced Interstitial Nephritis in the 21st Century
inferred← citeshttps://doi.org/10.1053/j.ackd.2021.02.001openalex-snapshot
Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned
inferred← citeshttps://doi.org/10.1053/j.ajkd.2017.05.025openalex-snapshot
Deprescribing in CKD: The Proof Is in the Process
inferred← citeshttps://doi.org/10.1053/j.ajkd.2019.07.012openalex-snapshot
Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe
inferred← citeshttps://doi.org/10.1053/j.ajkd.2021.03.019openalex-snapshot
Risk of Potentially Inappropriate Medications in Adults With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study
inferred← citeshttps://doi.org/10.1053/j.gastro.2017.01.031openalex-snapshot
The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association
inferred← citeshttps://doi.org/10.1053/j.gastro.2017.05.046openalex-snapshot
Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1053/j.gastro.2019.05.056openalex-snapshot
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
inferred← citeshttps://doi.org/10.1053/j.gastro.2022.06.067openalex-snapshot
Association of Proton Pump Inhibitor Use With All-Cause and Cause-Specific Mortality
inferred← citeshttps://doi.org/10.1080/00958972.2022.2143269openalex-snapshot
Urease inhibition and anti-leishmanial properties of Zn(II) complexes of thiophenyl and furyl-derived C2-symmetric ligands
inferred← citeshttps://doi.org/10.1080/01480545.2023.2282377openalex-snapshot
Omeprazole induces profibrotic gene expression in rat kidney: implication of TGF-β/Smad signaling pathway
inferred← citeshttps://doi.org/10.1080/03007995.2023.2233826openalex-snapshot
Impact of a multifaceted intervention on non-guideline-recommended prescribing of acid suppressive medications for stress ulcer prophylaxis in critically ill patients
inferred← citeshttps://doi.org/10.1080/0886022x.2024.2379596openalex-snapshot
Association between preoperative proton pump inhibitor use and postoperative acute kidney injury in patients undergoing major surgery
inferred← citeshttps://doi.org/10.1080/14740338.2019.1664470openalex-snapshot
Proton pump inhibitors, adverse events and increased risk of mortality
inferred← citeshttps://doi.org/10.1080/20009666.2019.1571881openalex-snapshot
Educational intervention can improve appropriateness of acid suppression therapy in hospitalized geriatric patients
inferred← citeshttps://doi.org/10.1088/1755-1315/125/1/012108openalex-snapshot
Association between neutrophil-to-lymphocyte ratio and survival rate patient hemodialysis in Adam Malik general hospital in 2016
inferred← citeshttps://doi.org/10.1093/ajhp/zxad009openalex-snapshot
Proton pump inhibitors: Understanding the associated risks and benefits of long-term use
inferred← citeshttps://doi.org/10.1093/ckj/sfaa244openalex-snapshot
Pharmacoepidemiology for nephrologists (part 1): concept, applications and considerations for study design
inferred← citeshttps://doi.org/10.1093/ckj/sfad109openalex-snapshot
Immune checkpoint inhibitors and their interaction with proton pump inhibitors–related interstitial nephritis
inferred← citeshttps://doi.org/10.1093/ckj/sfz046openalex-snapshot
Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study
inferred← citeshttps://doi.org/10.1093/ckj/sfz097openalex-snapshot
Inflammatory leucocyte infiltrates are associated with recovery in biopsy-proven acute interstitial nephritis: a 20-year registry-based case series
inferred← citeshttps://doi.org/10.1093/ckj/sfz138openalex-snapshot
AIN’t got no easy answers: recent advances and ongoing controversies around acute interstitial nephritis
inferred← citeshttps://doi.org/10.1093/eurheartj/ehz102openalex-snapshot
Combining DAPT with a PPI faces the acid test of real-world use
inferred← citeshttps://doi.org/10.1093/fampra/cmx102openalex-snapshot
Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study
inferred← citeshttps://doi.org/10.1093/joneph/aajag176openalex-snapshot
Chronic kidney disease progression with proton pump inhibitors versus H2 receptor antagonists in NSAID users
inferred← citeshttps://doi.org/10.1093/med/9780190611620.003.0012openalex-snapshot
Slowing Progression of Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1093/ndt/gfaa169openalex-snapshot
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
inferred← citeshttps://doi.org/10.1093/ndt/gfab346openalex-snapshot
Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data
inferred← citeshttps://doi.org/10.1093/ndt/gfag206openalex-snapshot
CKD risk with tegoprazan versus proton pump inhibitors
inferred← citeshttps://doi.org/10.1093/ndt/gfw349openalex-snapshot
Pharmacoepidemiology for nephrologists: do proton pump inhibitors cause chronic kidney disease?
inferred← citeshttps://doi.org/10.1093/ndt/gfw470openalex-snapshot
The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1093/qjmed/hcx021openalex-snapshot
Re: Ghebre Y., Raghu G. Proton pump inhibitors in IPF: beyond mere suppression of gastric acidity. QJM: An International Journal of Medicine 2016; 109:577–9
inferred← citeshttps://doi.org/10.1093/qjmed/hcz166openalex-snapshot
Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis
inferred← citeshttps://doi.org/10.1097/01.jaa.0000721664.47053.0eopenalex-snapshot
Magnetic sphincter augmentation device placement for treatment of gastroesophageal reflux
inferred← citeshttps://doi.org/10.1097/ccm.0000000000003633openalex-snapshot
Evaluation of Medication Errors at the Transition of Care From an ICU to Non-ICU Location
inferred← citeshttps://doi.org/10.1097/jcma.0000000000001280openalex-snapshot
Optimizing care for chronic kidney disease: Considerations from A to Z
inferred← citeshttps://doi.org/10.1097/mcg.0000000000000921openalex-snapshot
Association of Proton Pump Inhibitor Use With Serum Biomarkers of Inflammation, Insulin Resistance, Cardiovascular Risk, and Renal Function
inferred← citeshttps://doi.org/10.1097/mcg.0000000000001035openalex-snapshot
The Association Between Proton Pump Inhibitor Use With Acute Kidney Injury and Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1097/md.0000000000022509openalex-snapshot
Drug rash with eosinophilia and systemic symptoms and severe renal injury induced by proton pump inhibitor therapy
inferred← citeshttps://doi.org/10.1097/mnh.0000000000000406openalex-snapshot
The association of proton pump inhibitors and chronic kidney disease
inferred← citeshttps://doi.org/10.1097/nt.0000000000000244openalex-snapshot
Heartburn
inferred← citeshttps://doi.org/10.1097/spc.0000000000000332openalex-snapshot
Nonsteroidal anti-inflammatory drugs and cancer pain
inferred← citeshttps://doi.org/10.1101/2025.06.13.25329558openalex-snapshot
Proton pump inhibitors and upper gastrointestinal cancer: a matched case-control study addressing confounding by indication
inferred← citeshttps://doi.org/10.1111/1744-9987.13464openalex-snapshot
Esomeprazole vs pantoprazole effects on cyclosporine levels in kidney transplantation: A randomized clinical trial
inferred← citeshttps://doi.org/10.1111/bcpt.13763openalex-snapshot
Impact of combining vancomycin with proton pump inhibitors on the incidence of acute kidney injury
inferred← citeshttps://doi.org/10.1111/his.13064openalex-snapshot
Drug‐induced nephropathies
inferred← citeshttps://doi.org/10.1111/imj.14452openalex-snapshot
Proton‐pump inhibitor overuse: a cautionary tale in misguided benefit
inferred← citeshttps://doi.org/10.1111/jcmm.16302openalex-snapshot
Lansoprazole promotes cisplatin‐induced acute kidney injury via enhancing tubular necroptosis
inferred← citeshttps://doi.org/10.1111/jgh.13737openalex-snapshot
Proton pump inhibitors: Risks of long‐term use
inferred← citeshttps://doi.org/10.1111/jgh.14157openalex-snapshot
Acid‐suppressive drugs and risk of kidney disease: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1111/jgh.15151openalex-snapshot
Acute kidney injury following the use of different proton pump inhibitor regimens: A real‐world analysis of post‐marketing surveillance data
inferred← citeshttps://doi.org/10.1111/jvim.15337openalex-snapshot
ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats
inferred← citeshttps://doi.org/10.1111/nep.13567openalex-snapshot
Chronic kidney disease, Queensland: Profile of patients with chronic kidney disease from regional Queensland, Australia: A registry report
inferred← citeshttps://doi.org/10.1111/nyas.14447openalex-snapshot
Gastrointestinal pharmacology: practical tips for the esophagologist
inferred← citeshttps://doi.org/10.1136/archdischild-2017-314026openalex-snapshot
Toxicity of long-term use of proton pump inhibitors in children
inferred← citeshttps://doi.org/10.1136/bmj-2022-074216openalex-snapshot
Advances in the management of chronic kidney disease
inferred← citeshttps://doi.org/10.1136/bmj-2025-086886openalex-snapshot
Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study
inferred← citeshttps://doi.org/10.1136/bmj.l1580openalex-snapshot
Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study
inferred← citeshttps://doi.org/10.1136/bmj.m4677openalex-snapshot
Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study
inferred← citeshttps://doi.org/10.1136/bmjgast-2024-001723openalex-snapshot
Bone health, renal outcomes, and iron deficiency anaemia in proton pump inhibitor versus histamine-2 receptor antagonist users: a retrospective cohort study based on TriNetX global collaborative network data
inferred← citeshttps://doi.org/10.1136/bmjgh-2019-002063openalex-snapshot
The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: a modelling study
inferred← citeshttps://doi.org/10.1136/bmjopen-2016-015735openalex-snapshot
Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
inferred← citeshttps://doi.org/10.1136/bmjopen-2020-041543openalex-snapshot
Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case–control study
inferred← citeshttps://doi.org/10.1136/bmjopen-2023-078032openalex-snapshot
Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study
inferred← citeshttps://doi.org/10.1146/annurev-med-050223-112834openalex-snapshot
Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers
inferred← citeshttps://doi.org/10.1155/2020/8108730openalex-snapshot
Proton Pump Inhibitor-Induced Galactorrhea in a Kidney Transplant Recipient: A Friend or Foe?
inferred← citeshttps://doi.org/10.1155/2022/1904874openalex-snapshot
Urease and α-Chymotrypsin Inhibitory Activities and Molecular Docking Studies of Alkaloids Isolated from Medicinal Plant Isatis minima Bunge
inferred← citeshttps://doi.org/10.1159/000454831openalex-snapshot
Prevalence of Impaired Kidney Function in the German Elderly: Results from the Berlin Aging Study II (BASE-II)
inferred← citeshttps://doi.org/10.1159/000487154openalex-snapshot
Proton Pump Inhibitors: Are They a Real Threat to the Patient?
inferred← citeshttps://doi.org/10.1159/000531028openalex-snapshot
Long-Term Proton Pump Inhibitor Therapy Increases the Risk of Infection in Patients with Incident Hemodialysis
inferred← citeshttps://doi.org/10.1159/000538755openalex-snapshot
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
inferred← citeshttps://doi.org/10.1161/jaha.120.020237openalex-snapshot
Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium‐Glucose Cotransporter‐2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes
inferred← citeshttps://doi.org/10.1172/jci.insight.127456openalex-snapshot
Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
inferred← citeshttps://doi.org/10.1177/0003134821991988openalex-snapshot
Proton Pump Inhibitors, Associated Complications, and Alternative Therapies: A Shifting Risk Benefit Ratio
showing the first 200 of 333
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.